Vance L Albaugh1, Charles Robb Flynn1, Steven Cai1, Yi Xiao1, Robyn A Tamboli1, Naji N Abumrad1. 1. Department of Surgery (V.L.A., C.R.F., R.A.T., N.N.A.), Vanderbilt University Medical Center, Nashville, Tennessee 37232; Rosalind Franklin University (S.C.), North Chicago, Illinois 60064; and Department of Biochemistry (Y.X.), Vanderbilt University Medical Center, Nashville, Tennessee 37232.
Abstract
CONTEXT: Roux-en-Y gastric bypass (RYGB) is the most effective treatment for morbid obesity and resolution of diabetes. Over the last decade, it has become well accepted that this resolution of diabetes occurs before significant weight loss; however, the mechanisms behind this effect remain unknown and could represent novel therapeutic targets for obesity and diabetes. Bile acids have been identified as putative mediators of these weight loss-independent effects. OBJECTIVE: To identify the longitudinal changes in bile acids after RYGB, which may provide mechanistic insight into the weight loss-independent effects of RYGB. DESIGN: Observational study before/after intervention. SETTING: Academic medical center. PATIENTS/PARTICIPANTS: Samples were collected from morbidly obese patients (n = 21) before and after RYGB. INTERVENTION: RYGB. MAIN OUTCOME MEASURES: Seventeen individual bile acid species were measured preoperatively and at 1, 6, 12, and 24 months postoperatively. Anthropometric, hormonal, and hyperinsulinemic-euglycemic clamp data were also examined to identify physiological parameters associated with bile acid changes. RESULTS:Fasting total plasma bile acids increased after RYGB; however, increases were bimodal and were observed only at 1 (P < .05) and 24 months (P < .01). One-month increases were secondary to surges in ursodeoxycholic acid and its glycine and taurine conjugates, bacterially derived bile acids with putative insulin-sensitizing effects. Increases at 24 months were due to gradual rises in primary unconjugated bile acids as well as deoxycholic acid and its glycine conjugate. Plasma bile acid changes were not significantly associated with any anthropometric or hormonal measures, although hepatic insulin sensitivity was significantly improved at 1 month. CONCLUSIONS: Overall findings suggest that bacterially derived bile acids may mediate the early improvements at 1 month after RYGB. Future studies should examine the changes in specific bile acid chemical species after bariatric procedures and bile acid-specific signaling changes.
RCT Entities:
CONTEXT: Roux-en-Y gastric bypass (RYGB) is the most effective treatment for morbid obesity and resolution of diabetes. Over the last decade, it has become well accepted that this resolution of diabetes occurs before significant weight loss; however, the mechanisms behind this effect remain unknown and could represent novel therapeutic targets for obesity and diabetes. Bile acids have been identified as putative mediators of these weight loss-independent effects. OBJECTIVE: To identify the longitudinal changes in bile acids after RYGB, which may provide mechanistic insight into the weight loss-independent effects of RYGB. DESIGN: Observational study before/after intervention. SETTING: Academic medical center. PATIENTS/PARTICIPANTS: Samples were collected from morbidly obesepatients (n = 21) before and after RYGB. INTERVENTION: RYGB. MAIN OUTCOME MEASURES: Seventeen individual bile acid species were measured preoperatively and at 1, 6, 12, and 24 months postoperatively. Anthropometric, hormonal, and hyperinsulinemic-euglycemic clamp data were also examined to identify physiological parameters associated with bile acid changes. RESULTS: Fasting total plasma bile acids increased after RYGB; however, increases were bimodal and were observed only at 1 (P < .05) and 24 months (P < .01). One-month increases were secondary to surges in ursodeoxycholic acid and its glycine and taurine conjugates, bacterially derived bile acids with putative insulin-sensitizing effects. Increases at 24 months were due to gradual rises in primary unconjugated bile acids as well as deoxycholic acid and its glycine conjugate. Plasma bile acid changes were not significantly associated with any anthropometric or hormonal measures, although hepatic insulin sensitivity was significantly improved at 1 month. CONCLUSIONS: Overall findings suggest that bacterially derived bile acids may mediate the early improvements at 1 month after RYGB. Future studies should examine the changes in specific bile acid chemical species after bariatric procedures and bile acid-specific signaling changes.
Authors: Dimitri J Pournaras; Clare Glicksman; Royce P Vincent; Shophia Kuganolipava; Jamie Alaghband-Zadeh; David Mahon; Jan H R Bekker; Mohammad A Ghatei; Stephen R Bloom; Julian R F Walters; Richard Welbourn; Carel W le Roux Journal: Endocrinology Date: 2012-06-06 Impact factor: 4.736
Authors: Malin Werling; Royce P Vincent; Gemma F Cross; Hanns-Ulrich Marschall; Lars Fändriks; Hans Lönroth; David R Taylor; Jamshid Alaghband-Zadeh; Torsten Olbers; Carel W Le Roux Journal: Scand J Gastroenterol Date: 2013-09-18 Impact factor: 2.423
Authors: Rohit Kohli; David Bradley; Kenneth D Setchell; J Christopher Eagon; Nada Abumrad; Samuel Klein Journal: J Clin Endocrinol Metab Date: 2013-03-01 Impact factor: 5.958
Authors: Alice P Liou; Melissa Paziuk; Jesus-Mario Luevano; Sriram Machineni; Peter J Turnbaugh; Lee M Kaplan Journal: Sci Transl Med Date: 2013-03-27 Impact factor: 17.956
Authors: Fei Li; Changtao Jiang; Kristopher W Krausz; Yunfei Li; Istvan Albert; Haiping Hao; Kristin M Fabre; James B Mitchell; Andrew D Patterson; Frank J Gonzalez Journal: Nat Commun Date: 2013 Impact factor: 14.919
Authors: Glenn S Gerhard; Amanda M Styer; G Craig Wood; Stephen L Roesch; Anthony T Petrick; Jon Gabrielsen; William E Strodel; Christopher D Still; George Argyropoulos Journal: Diabetes Care Date: 2013-07 Impact factor: 19.112
Authors: Robyn A Tamboli; Tahar Hajri; Aixiang Jiang; Pamela A Marks-Shulman; D Brandon Williams; Ronald H Clements; Willie Melvin; Benjamin P Bowen; Yu Shyr; Naji N Abumrad; Charles Robb Flynn Journal: PLoS One Date: 2011-12-16 Impact factor: 3.240
Authors: Sangeeta R Kashyap; Deepak L Bhatt; Kathy Wolski; Richard M Watanabe; Muhammad Abdul-Ghani; Beth Abood; Claire E Pothier; Stacy Brethauer; Steven Nissen; Manjula Gupta; John P Kirwan; Philip R Schauer Journal: Diabetes Care Date: 2013-02-25 Impact factor: 19.112
Authors: Viktoria L Gloy; Matthias Briel; Deepak L Bhatt; Sangeeta R Kashyap; Philip R Schauer; Geltrude Mingrone; Heiner C Bucher; Alain J Nordmann Journal: BMJ Date: 2013-10-22
Authors: O Chávez-Talavera; G Baud; V Spinelli; M Daoudi; M Kouach; J-F Goossens; E Vallez; R Caiazzo; M Ghunaim; T Hubert; S Lestavel; A Tailleux; B Staels; F Pattou Journal: Int J Obes (Lond) Date: 2017-01-17 Impact factor: 5.095
Authors: Kristen E Syring; Travis J Cyphert; Thomas C Beck; Charles R Flynn; Nicholas A Mignemi; Owen P McGuinness Journal: Am J Physiol Endocrinol Metab Date: 2019-02-19 Impact factor: 4.310
Authors: V Spinelli; F Lalloyer; G Baud; E Osto; M Kouach; M Daoudi; E Vallez; V Raverdy; J-F Goossens; A Descat; P Doytcheva; T Hubert; T A Lutz; S Lestavel; B Staels; F Pattou; A Tailleux Journal: Int J Obes (Lond) Date: 2016-03-22 Impact factor: 5.095